anti hypertensive agents

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathstroke (fatal and non fatal)

diabetes type 2

amlodipine
IDNT (amlodipine vs PBO), 2001       amlodipineplaceboLow risk of bias negative-12%
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002       amlodipinechlorthalidoneLow risk of bias negative-4%-11%
FACET, 1997     amlodipinefosinoprilRisk of bias suggesting-19%147%
candesartan
SCOPE (diabetic subgroup), 2003       candesartancontrolLow risk of bias negative-9%
captopril
UKPDS 38, 1998     captopril or atenololcontrolExploratory suggesting -17%-42%
UKPDS 39, 1998     captoprilatenololExploratory negative 14%38%
CAPP (diabetic subgroup), 1999       captoprildiuretic and/or beta-blockersExploratory suggesting -46%3%
chlorthalidone
SHEP (diabetic subgroup), 1996   chlorthalidoneplaceboLow risk of bias suggesting -26%-26%
intensive blood pressure lowering strategies
ABCD target (H) , 2000   more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-55%-2%
ABCD target (N) , 2002     more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-8%-68%
irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002       lisinoprilchlorthalidoneLow risk of bias negative-1%6%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
LIFE (diabetic subgroup), 2002       losartanatenololLow risk of bias suggesting-39%-18%
metoprolol
MERIT-HF, 2005     metoprololplaceboLow risk of bias negative-19%
nidrendipine
Syst-Eur (diabetic subgroup), 1999     nitrendipineplaceboLow risk of bias suggesting-41%-68%
nifedipine
INSIGHT (diabetic subgroup), 2000       nifedipinecoamilozideLow risk of bias negative-25%-10%
nisoldipine
ABCD (hypertension), 1998     nisoldipineenalaprilLow risk of bias suggesting-23%57%
olmesartan
ROADMAP, 2010        NCTolmesartanplaceboLow risk of bias suggesting 72%
ORIENT    NCTolmesartanplaceboLow risk of bias negative-4%
ramipril
DIABHYCAR, 2004     ramiprilplaceboLow risk of bias negative 4%3%
DREAM, 2008       ramiprilplacebonegative-2%-50%

hypertension

aliskiren
ACCELERATE, 2011    NCTaliskiren amlodipine -
AVOID, 2008      NCTaliskirenplaceboLow risk of bias negative-100%
Schmieder (vs HCTZ), 2009     aliskirenhydrochlorothiazideLow risk of bias negative
ALLAY, 2009      NCTaliskirenlosartanExploratory negative
Andersen, 2008     aliskirenramiprilLow risk of bias -
amlodipine
IDNT (amlodipine vs PBO), 2001       amlodipineplaceboLow risk of bias negative-12%
IDNT (amlodipine vs pbo), 2001     amlodipineplaceboLow risk of bias negative-10%
Tepel et al, 2008      NCTamlodipineplaceboLow risk of bias negative-22%
ASCOT-BPLA, 2005     amlodipineatenololRisk of bias suggesting-10%-23%
ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002       amlodipinechlorthalidoneLow risk of bias negative-4%-11%
ALLHAT (CCB vs diu), 2002     amlodipinechlorthalidonenegative -4%-6%
FACET, 1997     amlodipinefosinoprilRisk of bias suggesting-19%147%
ACCOMPLISH, 2008        NCTamlodipine plus benazeprilhydrochlorothiazide plus benazeprilLow risk of bias suggesting-10%-16%
ALLHAT (CCB vs ACEI), 2002     amlodipinelisinoprilsuggesting-4%-17%
AASK (amlodipine vs metoprolol), 2002     amlodipinemetoprololnegative-30%
atenolol
Coope, 1986   atenololcontrol suggesting-3%
Coope (subgroup ), 1986   atenololcontrolLow risk of bias negative-100%
MRC old (vs placebo), 1992   atenololplaceboLow risk of bias negative6%
MRC I (vs placebo), 1985   atenololplaceboLow risk of bias suggesting-7%
Dutch TIA, 1993   atenololplaceboLow risk of bias suggesting12%
TEST, 1995   atenololplacebonegative-20%
MRC I (vs diuretics), 1985   atenololbendroflumethiazideLow risk of bias negative 22%
MRC old (vs diuretics), 1992   atenololhydrochlorothiazide+amilorideLow risk of bias negative 22%
candesartan
Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%-42%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%-11%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%-8%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-23%
TROPHY, 2006      NCTcandesartanplaceboLow risk of bias suggesting
HSCS, 1974   deserpidine +methylclothiazideplaceboLow risk of bias negative2%-17%
Takahashi et al, 2006     candesartanusual caresuggesting-100%
Suzuki et al, 2008     candesartanusual caresuggesting-34%
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%27%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting
captopril
UKPDS 38, 1998     captopril or atenololcontrolExploratory suggesting -17%-42%
UKPDS 39, 1998     captoprilatenololExploratory negative 14%38%
CAPP (diabetic subgroup), 1999       captoprildiuretic and/or beta-blockersExploratory suggesting -46%3%
UKPDS-HDS, 1998       captoprildiuretic or beta-blockernegative14%11%
CAPPP, 1999     captoprildiuretic or beta-blockerRisk of bias negative -3%28%
carvedilol
Cice et al, 2003     carvedilolplacebosuggesting
Nakao et al, 2007   carvedilolplacebo -
chlorthalidone
SHEP (diabetic subgroup), 1996   chlorthalidoneplaceboLow risk of bias suggesting -26%-26%
VA-NHLBI, 1977   chlorthalidoneplacebonegative+Infini%
SHEP, 1991      NCTchlorthalidoneplaceboLow risk of bias suggesting -12%-35%
SHEP-pilot, 1989   chlorthalidoneplaceboLow risk of bias negative
SHEP-P (subgroup ), 1989   chlorthalidoneplaceboLow risk of bias suggesting+Infini%-79%
SHEP (subgroup ), 1991   chlorthalidoneplaceboLow risk of bias suggesting-7%-47%
diltiazem
NORDIL, 2000     diltiazemdiuretic or beta-blockersuggesting2%-18%
enalapril
ANBP2, 2003     enalaprildiureticsRisk of bias negative-7%5%
ABCD (H), 1998     enalaprilnisoldipineLow risk of bias suggesting-22%-36%
fosinopril
Zannad et al, 2006     fosinoprilplaceboLow risk of bias negative9%
hydrochlorothiazide
EWPHE (subgroup ), 1985   hydrochlorothiazideplaceboLow risk of bias negative17%
Kuramoto, 1981   hydrochlorothiazide + triamtereneplaceboLow risk of bias negative
EWPHE, 1985   hydrochlorothiazide + triamtereneplaceboLow risk of bias suggesting
indapamide
HYVET pilot, 2003   -
HYVET, 2008    NCTindapamideplaceboLow risk of bias suggesting -18%-27%
PATS, 1995   indapamideplaceboLow risk of bias negative -8%-27%
HAPPY, 1987   negative
intensive blood pressure lowering strategies
ABCD target (H) , 2000   more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-55%-2%
ABCD target (N) , 2002     more intensive blood pressure lowering strategieless intensive blood pressure lowering strategie type 2 diabetes suggesting-8%-68%
irbesartan
IPDM (150mg), 2001     irbesartanplaceboLow risk of bias suggesting
IDNT (irbesartan vs pbo), 2001     irbesartanplaceboLow risk of bias suggesting-8%
IRMA 2, 2001     irbesartanplaceboLow risk of bias negative13%
IDNT (irbesartan vs pbo), 2001       irbesartanplaceboLow risk of bias negative-8%6%
IDNT (irbesartan vs amlodipine), 2001     irbesartanamlodipineLow risk of bias suggesting4%
isradipine
MIDAS, 1996   isradipinehydrochlorothiazidenegative-11%100%
lacidipine
ELSA, 2002     lacidipineatenololLow risk of bias -
SHELL, 2003   lacidipinechlorthalidone -
lisinopril
ALLHAT (ACEI vs amlodipine), 2002     lisinoprilamlodipineLow risk of bias suggesting 5%21%
ALLHAT (lisi vs chlor, diabetic subgroup), 2002       lisinoprilchlorthalidoneLow risk of bias negative-1%6%
ALLHAT (ACEI vs chlorthalidone), 2002     lisinoprildiureticsLow risk of bias negative 0%14%
losartan
RENAAL, 2001     losartanplaceboLow risk of bias suggesting2%
RENAAL, 2001     losartanplaceboLow risk of bias -
LIFE (diabetic subgroup), 2002       losartanatenololLow risk of bias suggesting-39%-18%
LIFE, 2002     losartanatenololLow risk of bias suggesting -11%-25%
nicardipine
NICS-EH, 1999     nicardipinetrichlormethiazideLow risk of bias negative0%-25%
nidrendipine
Syst-Eur (subgroup ), 1997     nidrendipineplaceboLow risk of bias negative23%-23%
SYST-EUR, 1997     nitrendipineplacebosuggesting-14%